FibroGen to Report Fiscal 2016 Financial Results 

SAN FRANCISCO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN ), a science-based biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2016, on Wednesday, March 1, 2017, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).

Audio Webcast Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com . It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 4425 2209#.

Dial-In Information Live (U.S. / Canada): (888) 771-4371 Live (International): (847) 585-4405 Confirmation number: 44252209

About FibroGen FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics.  The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.  Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in CKD.  Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne’s muscular dystrophy (DMD).  FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com .

Contact Karen L. Bergman Vice President, Investor Relations and Corporate Communications FibroGen, Inc. (415) 978-1433 kbergman@fibrogen.com